Efficacy, toxicity and prognostic factors of pyrotinib‑involved neoadjuvant therapy in HER2‑positive breast cancer: A retrospective study.

Oncol Lett · 2023 · PMC10272951 · PMID 37332338

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

IHC++ and gene amplification by FISH; O, 8.453; 95% CI, 0.879-81.315; P=0.065) only showed a trend (without statistical significance) of independently link with tpCR.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.